$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913084831 Filed on November 14, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$4.411M	$16.29M	$7.195M
YoY Change	-33.57%	126.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.500M	$6.700M	$3.800M
YoY Change	134.38%	76.32%
% of Gross Profit
Research & Development	$15.00M	$13.89M	$10.47M
YoY Change	57.89%	32.67%
% of Gross Profit
Depreciation & Amortization	$590.0K	$590.0K	$670.0K
YoY Change	-9.23%	-11.94%
% of Gross Profit
Operating Expenses	$22.50M	$20.57M	$14.25M
YoY Change	77.55%	44.31%
Operating Profit	-$18.09M	-$4.276M	-$7.055M
YoY Change	199.82%	-39.4%
Interest Expense	$200.0K	$26.70K	-$247.3K
YoY Change	-200.0%	-110.79%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$37.62K	$5.507K
YoY Change		-783.06%
Pretax Income	-$17.90M	-$4.400M	-$7.300M
YoY Change	184.13%	-39.73%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.89M	-$4.416M	-$7.297M
YoY Change	185.17%	-39.48%
Net Earnings / Revenue	-405.5%	-27.11%	-101.42%
Basic Earnings Per Share	-$0.75	-$0.19	-$1.606K
Diluted Earnings Per Share	-$0.75	-$0.19	-$1.606K
COMMON SHARES
Basic Shares Outstanding	24.92M shares	23.80M shares	4.545K shares
Diluted Shares Outstanding		23.80M shares	4.545K shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$142.5M	$157.2M
YoY Change	5127.44%
Cash & Equivalents	$15.41M	$24.04M	$14.47M
Short-Term Investments	$127.1M	$133.2M
Other Short-Term Assets	$1.600M	$2.100M
YoY Change
Inventory
Prepaid Expenses
Receivables	$1.000M	$800.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$145.0M	$160.1M
YoY Change	3055.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.730M	$6.943M
YoY Change	-18.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$200.0K
YoY Change
Total Long-Term Assets	$6.879M	$7.106M
YoY Change	-18.85%
TOTAL ASSETS
Total Short-Term Assets	$145.0M	$160.1M
Total Long-Term Assets	$6.879M	$7.106M
Total Assets	$151.9M	$167.2M
YoY Change	1062.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.124M	$1.017M
YoY Change	80.83%
Accrued Expenses	$5.100M	$3.100M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$49.00K	$84.23K
YoY Change	-98.9%
Total Short-Term Liabilities	$13.13M	$13.92M
YoY Change	-53.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$2.227M	$2.290M
YoY Change	-12.66%
Total Long-Term Liabilities	$2.227M	$2.290M
YoY Change	-25.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.13M	$13.92M
Total Long-Term Liabilities	$2.227M	$2.290M
Total Liabilities	$15.36M	$16.21M
YoY Change	-51.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$328.8M	-$310.9M
YoY Change	18.6%
Common Stock	$24.00K	$24.34K
YoY Change	4303.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$136.5M	$151.0M
YoY Change
Total Liabilities & Shareholders Equity	$151.9M	$167.2M
YoY Change	1062.02%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$17.89M	-$4.416M	-$7.297M
YoY Change	185.17%	-39.48%
Depreciation, Depletion And Amortization	$590.0K	$590.0K	$670.0K
YoY Change	-9.23%	-11.94%
Cash From Operating Activities	-$14.46M	-$5.180M	-$6.200M
YoY Change	30.98%	-16.45%
INVESTING ACTIVITIES
Capital Expenditures	-$380.0K	-$370.0K	$0.00
YoY Change	3700.0%
Acquisitions
YoY Change
Other Investing Activities	$6.240M	-$121.6M	$0.00
YoY Change
Cash From Investing Activities	$5.870M	-$122.0M	$0.00
YoY Change	-58800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-30.00K	-2.860M	-1.580M
YoY Change	-95.71%	81.01%
NET CHANGE
Cash From Operating Activities	-14.46M	-5.180M	-6.200M
Cash From Investing Activities	5.870M	-122.0M	0.000
Cash From Financing Activities	-30.00K	-2.860M	-1.580M
Net Change In Cash	-8.620M	-130.1M	-7.780M
YoY Change	-26.64%	1571.72%
FREE CASH FLOW
Cash From Operating Activities	-$14.46M	-$5.180M	-$6.200M
Capital Expenditures	-$380.0K	-$370.0K	$0.00
Free Cash Flow	-$14.08M	-$4.810M	-$6.200M
YoY Change	27.65%	-22.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24917089	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	PTC THERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	84234	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-310912330	USD
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	133223032	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	40169	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	80636	USD
CY2013Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	133182565	USD
CY2013Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	133182565	USD
CY2013Q3	ptct	Available For Sale Securities Debt Maturities Over One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesOverOneYearAmortizedCost	50358678	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3096475	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3659084	USD
CY2012Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	2515678	USD
CY2013Q3	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	3556350	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	559228	USD
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1532458	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	621591	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1017122	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	230999	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	440479	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7023971	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10205493	USD
CY2013Q1	ptct	Proceeds From Issuance Of Convertible Preferred Stock And Short Term Debt ProceedsFromIssuanceOfConvertiblePreferredStockAndShortTermDebt	60000000	USD
	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	3390750	USD
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-33687612	USD
	ptct	Deemed Dividend DeemedDividend	18248768	USD
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1605.53
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2126575	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7297125	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4416499	USD
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4545	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23803282	shares
CY2013Q3	ptct	Grant And Other Receivables GrantAndOtherReceivables	783851	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	160137810	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6942956	USD
CY2013Q3	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	163349	USD
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1605.53
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48545630	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2937	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8995167	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	10656	shares
	us-gaap	Net Income Loss NetIncomeLoss	-19963058	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3631430	USD
	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	159954069	USD
	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	377787	USD
	us-gaap	Participating Securities Distributed And Undistributed Earnings ParticipatingSecuritiesDistributedAndUndistributedEarnings	139077495	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2290445	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	535729	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13593	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8995167	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	182.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	39.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.40
CY2013Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-129963	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-129963	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	24344	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2725702	USD
CY2012Q4	us-gaap	Assets Assets	13072352	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	855750	USD
CY2012Q4	ptct	Grant And Other Receivables GrantAndOtherReceivables	1013813	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	4595265	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8280037	USD
CY2012Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	197050	USD
CY2013Q3	us-gaap	Assets Assets	167244115	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4444171	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16690747	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28158889	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	741667	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	438810	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2549719	USD
CY2012Q4	us-gaap	Liabilities Liabilities	31889085	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	545	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177583672	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-40467	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-277224718	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-99640501	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13072352	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13921157	USD
CY2013Q3	us-gaap	Liabilities Liabilities	16211602	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	167244115	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	16289573	USD
	us-gaap	Operating Expenses OperatingExpenses	57590409	USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4526	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	17000000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4526	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23803282	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23803282	shares
CY2012Q3	ptct	Collaboration Revenue CollaborationRevenue	6042746	USD
	ptct	Collaboration Revenue CollaborationRevenue	22860543	USD
CY2012Q3	us-gaap	Revenue From Grants RevenueFromGrants	1152330	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10466454	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	7195076	USD
	us-gaap	Revenue From Grants RevenueFromGrants	4445430	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3783929	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	27305973	USD
	us-gaap	Operating Expenses OperatingExpenses	48079724	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20773751	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1007586	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	30285449	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	14250383	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7055307	USD
CY2012Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-247325	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5507	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36688786	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11390938	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1818279	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	-7297125	USD
	us-gaap	Profit Loss ProfitLoss	139613224	USD
CY2013Q3	us-gaap	Profit Loss ProfitLoss	-4416499	USD
CY2013Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-39695	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-40467	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7297125	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19963058	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33728079	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4456194	USD
	us-gaap	Depreciation Depreciation	2048682	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1818279	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	204422	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1815722	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2250089	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-75698	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-24399	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4748005	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-68432	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16711980	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-36890742	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	183511	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-183511	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	461960966	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	139730579	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6507547	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-32458982	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6240116	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	29354752	USD
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	60785363	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	131649688	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23114636	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	187474900	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	21319117	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-13959617	USD
	us-gaap	Interest Paid InterestPaid	1009478	USD
	ptct	Change In Carrying Value Of Preferred Securities Resulting From Recapitalization ChangeInCarryingValueOfPreferredSecuritiesResultingFromRecapitalization	159576282	USD
	ptct	Change In Unrealized Loss On Marketable Securities ChangeInUnrealizedLossOnMarketableSecurities	-40467	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44218	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28431410	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14471793	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.             The Company</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">PTC Therapeutics, Inc. (the Company or PTC) was incorporated as a Delaware corporation on March 31, 1998. The Company is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has devoted substantially all of its efforts to research and development, including clinical trials. The Company has not completed development of any drugs. The Company has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, the difficulties inherent in the development of commercially usable products, the potential need to obtain additional capital necessary to fund the development of its products, and competition from other companies. As of September 30, 2013, the Company had an accumulated deficit of approximately $310.9 million. The Company has financed its operations to date primarily through the issuance and sale of its common stock in its initial public offering (see note 7 below), private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by the Company’s product candidates. The Company believes that its existing cash, cash equivalents, including the Company’s net proceeds from its initial public offering of common stock, and marketable securities provide for sufficient resources to fund its currently planned operations through the fourth quarter of 2015.</font></p> </div>
CY2013Q3	ptct	Milestone Payments Received MilestonePaymentsReceived	10000000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	20565188	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27304960	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4275615	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-133696801	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24044819	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	151032513	USD
CY2013Q3	ptct	Collaboration Revenue CollaborationRevenue	15455361	USD
	ptct	Collaboration Revenue CollaborationRevenue	27395315	USD
CY2013Q3	us-gaap	Revenue From Grants RevenueFromGrants	834212	USD
	us-gaap	Revenue From Grants RevenueFromGrants	2890134	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13886196	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39855115	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6678992	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17735294	USD
CY2013Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	26695	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-6249534	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37616	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3155	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-7297125	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-4416499	USD
	us-gaap	Profit Loss ProfitLoss	-48545630	USD
	us-gaap	Depreciation Depreciation	1810850	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3158	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	6048580	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5142187	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1287875	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-229962	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-33699	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3181522	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-262432	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13800984	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	473769	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4960151	USD
	us-gaap	Interest Paid InterestPaid	365589	USD
	ptct	Change In Carrying Value Of Preferred Securities Resulting From Recapitalization ChangeInCarryingValueOfPreferredSecuritiesResultingFromRecapitalization	3390750	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3101667	shares
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1605.53
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4545	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23803282	shares
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-772	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-39695	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-40467	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-39695	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-40467	USD
CY2013Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	2600000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	520400	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2639696	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1815722	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5142187	USD
CY2012Q4	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2013Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	82823887	USD

Files In Submission

Name	View Source	Status
0001104659-13-084831-index-headers.html	Edgar Link	pending
0001104659-13-084831-index.html	Edgar Link	pending
0001104659-13-084831.txt	Edgar Link	pending
0001104659-13-084831-xbrl.zip	Edgar Link	pending
a13-19854_110q.htm	Edgar Link	pending
a13-19854_1ex31d1.htm	Edgar Link	pending
a13-19854_1ex31d2.htm	Edgar Link	pending
a13-19854_1ex32d1.htm	Edgar Link	pending
a13-19854_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ptct-20130930.xml	Edgar Link	completed
ptct-20130930.xsd	Edgar Link	pending
ptct-20130930_cal.xml	Edgar Link	unprocessable
ptct-20130930_def.xml	Edgar Link	unprocessable
ptct-20130930_lab.xml	Edgar Link	unprocessable
ptct-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

2013 Q4 Form 10-Q Financial Statement

#000110465913084831 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC THERAPEUTICS, INC. Stock $ptct

2013 Q4 Form 10-Q Financial Statement

#000110465913084831 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct